Cargando…

An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment

In severe cases, Parkinson’s disease causes uncontrolled movements known as motor symptoms such as dystonia, rigidity, bradykinesia, and tremors. Parkinson’s disease also causes non-motor symptoms such as insomnia, constipation, depression and hysteria. Disruption of dopaminergic and non-dopaminergi...

Descripción completa

Detalles Bibliográficos
Autores principales: Adam, Hussaini, Gopinath, Subash C. B., Md Arshad, M. K., Adam, Tijjani, Parmin, N. A., Husein, Irzaman, Hashim, Uda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134733/
https://www.ncbi.nlm.nih.gov/pubmed/37124989
http://dx.doi.org/10.1007/s13205-023-03553-8
_version_ 1785031821740736512
author Adam, Hussaini
Gopinath, Subash C. B.
Md Arshad, M. K.
Adam, Tijjani
Parmin, N. A.
Husein, Irzaman
Hashim, Uda
author_facet Adam, Hussaini
Gopinath, Subash C. B.
Md Arshad, M. K.
Adam, Tijjani
Parmin, N. A.
Husein, Irzaman
Hashim, Uda
author_sort Adam, Hussaini
collection PubMed
description In severe cases, Parkinson’s disease causes uncontrolled movements known as motor symptoms such as dystonia, rigidity, bradykinesia, and tremors. Parkinson’s disease also causes non-motor symptoms such as insomnia, constipation, depression and hysteria. Disruption of dopaminergic and non-dopaminergic neural networks in the substantia nigra pars compacta is a major cause of motor symptoms in Parkinson’s disease. Furthermore, due to the difficulty of clinical diagnosis of Parkinson’s disease, it is often misdiagnosed, highlighting the need for better methods of detection. Treatment of Parkinson’s disease is also complicated due to the difficulties of medications passing across the blood–brain barrier. Moreover, the conventional methods fail to solve the aforementioned issues. As a result, new methods are needed to detect and treat Parkinson's disease. Improved diagnosis and treatment of Parkinson's disease can help avoid some of its devastating symptoms. This review explores how nanotechnology platforms, such as nanobiosensors and nanomedicine, have improved Parkinson’s disease detection and treatment. Nanobiosensors integrate science and engineering principles to detect Parkinson’s disease. The main advantages are their low cost, portability, and quick and precise analysis. Moreover, nanotechnology can transport medications in the form of nanoparticles across the blood–brain barrier. However, because nanobiosensors are a novel technology, their use in biological systems is limited. Nanobiosensors have the potential to disrupt cell metabolism and homeostasis, changing cellular molecular profiles and making it difficult to distinguish sensor-induced artifacts from fundamental biological phenomena. In the treatment of Parkinson’s disease, nanoparticles, on the other hand, produce neurotoxicity, which is a challenge in the treatment of Parkinson’s disease. Techniques must be developed to distinguish sensor-induced artifacts from fundamental biological phenomena and to reduce the neurotoxicity caused by nanoparticles.
format Online
Article
Text
id pubmed-10134733
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101347332023-04-28 An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment Adam, Hussaini Gopinath, Subash C. B. Md Arshad, M. K. Adam, Tijjani Parmin, N. A. Husein, Irzaman Hashim, Uda 3 Biotech Review Article In severe cases, Parkinson’s disease causes uncontrolled movements known as motor symptoms such as dystonia, rigidity, bradykinesia, and tremors. Parkinson’s disease also causes non-motor symptoms such as insomnia, constipation, depression and hysteria. Disruption of dopaminergic and non-dopaminergic neural networks in the substantia nigra pars compacta is a major cause of motor symptoms in Parkinson’s disease. Furthermore, due to the difficulty of clinical diagnosis of Parkinson’s disease, it is often misdiagnosed, highlighting the need for better methods of detection. Treatment of Parkinson’s disease is also complicated due to the difficulties of medications passing across the blood–brain barrier. Moreover, the conventional methods fail to solve the aforementioned issues. As a result, new methods are needed to detect and treat Parkinson's disease. Improved diagnosis and treatment of Parkinson's disease can help avoid some of its devastating symptoms. This review explores how nanotechnology platforms, such as nanobiosensors and nanomedicine, have improved Parkinson’s disease detection and treatment. Nanobiosensors integrate science and engineering principles to detect Parkinson’s disease. The main advantages are their low cost, portability, and quick and precise analysis. Moreover, nanotechnology can transport medications in the form of nanoparticles across the blood–brain barrier. However, because nanobiosensors are a novel technology, their use in biological systems is limited. Nanobiosensors have the potential to disrupt cell metabolism and homeostasis, changing cellular molecular profiles and making it difficult to distinguish sensor-induced artifacts from fundamental biological phenomena. In the treatment of Parkinson’s disease, nanoparticles, on the other hand, produce neurotoxicity, which is a challenge in the treatment of Parkinson’s disease. Techniques must be developed to distinguish sensor-induced artifacts from fundamental biological phenomena and to reduce the neurotoxicity caused by nanoparticles. Springer International Publishing 2023-04-27 2023-05 /pmc/articles/PMC10134733/ /pubmed/37124989 http://dx.doi.org/10.1007/s13205-023-03553-8 Text en © King Abdulaziz City for Science and Technology 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
spellingShingle Review Article
Adam, Hussaini
Gopinath, Subash C. B.
Md Arshad, M. K.
Adam, Tijjani
Parmin, N. A.
Husein, Irzaman
Hashim, Uda
An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
title An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
title_full An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
title_fullStr An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
title_full_unstemmed An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
title_short An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
title_sort update on pathogenesis and clinical scenario for parkinson’s disease: diagnosis and treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134733/
https://www.ncbi.nlm.nih.gov/pubmed/37124989
http://dx.doi.org/10.1007/s13205-023-03553-8
work_keys_str_mv AT adamhussaini anupdateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT gopinathsubashcb anupdateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT mdarshadmk anupdateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT adamtijjani anupdateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT parminna anupdateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT huseinirzaman anupdateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT hashimuda anupdateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT adamhussaini updateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT gopinathsubashcb updateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT mdarshadmk updateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT adamtijjani updateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT parminna updateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT huseinirzaman updateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment
AT hashimuda updateonpathogenesisandclinicalscenarioforparkinsonsdiseasediagnosisandtreatment